News & Events about Oncocyte Corp.
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation(Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocytes workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has ...
OncoCyte (NASDAQ:OCX Get Rating) and Lucira Health (NASDAQ:LHDX Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, ...
OncoCyte (NASDAQ:OCX Get Rating) had its price target cut by Benchmark to $3.00 in a research report sent to investors on Thursday, Stock Target Advisor reports. A number of other equities analysts have also weighed in on OCX. Needham & Company LLC lowered their target price on OncoCyte from $2.10 ...
Ticker Report
2 months ago
Piper Sandler lowered shares of OncoCyte (NASDAQ:OCX Get Rating) from an overweight rating to a neutral rating in a research note released on Thursday morning, The Fly reports. The brokerage currently has $0.50 target price on the stock, down from their previous target price of $1.00. OCX ...
Ticker Report
2 months ago
OncoCyte (NASDAQ:OCX Get Rating) had its price objective trimmed by Benchmark to $3.00 in a report released on Thursday morning, Stock Target Advisor reports. Several other research firms have also recently issued reports on OCX. Piper Sandler cut shares of OncoCyte from an overweight rating...